問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

郭明濬
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

106Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

郭明濬

List

138Cases

2025-05-01 - 2028-07-31

Phase II

Active
A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Subjects with Metastatic Colorectal Cancer (AndroMETa-CRC-533)

  • Condition/Disease

    Metastatic colorectal cancer (mCRC)

  • Test Drug

    ABBV-400

Participate Sites
6Sites

Recruiting6Sites

2025-12-01 - 2032-01-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

2020-07-01 - 2027-07-31

Phase I

Active
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Locally Advanced or Metastatic Solid Tumors

  • Test Drug

    ABBV-151

Participate Sites
6Sites

Recruiting6Sites

2022-12-01 - 2024-10-28

Phase II

Active
Phase 2, Open-Label Study in Subjects With Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non Small Cell Lung Cancer

  • Test Drug

    Telisotuzumab vedotin (ABBV-399)

Participate Sites
4Sites

Recruiting4Sites

2023-12-31 - 2026-03-18

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
8Sites

Recruiting8Sites

2020-05-12 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-10-01 - 2029-06-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-06-18 - 2027-12-31

Phase I

Not yet recruiting
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

  • Condition/Disease

    Neoplasms

  • Test Drug

    注射劑

Participate Sites
6Sites

Recruiting6Sites

2024-01-01 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-06-28 - 2027-03-31

Phase III

Active
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

  • Condition/Disease

    Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

  • Test Drug

    GIREDESTRANTEVEROLIMUSEXEMESTANETAMOXIFENFULVESTRANT

Participate Sites
6Sites

Recruiting6Sites

1 3 4 5 6 7 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB